Chronic hepatitis B
Conditions
Interventions
Start PEG-IFN alpha 2a administration just after stopping NA.
Sponsors
Department of Medicine, Shinshu University School of Medicine
Division of Hepatobiliary and Pancreatic Medicine, Hyogo College of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with chronic hepatitis B who have been treated with NA for more than one years. 2. Patients who understand a risk of hepatitis relapse after stopping NA. 3. Patients who can be followed properly after stopping NA. 4. Patients whose informed consent was obtained.
Exclusion criteria
Exclusion criteria: 1. Patients with impaired liver function. 2. Patients with advance liver fibrosis. 3. Patients with other serious diseases. 4. Women who are pregnant or those who have a possibility to be pregnant. 5. Patients who have a contra-indication for receiving PEG-IFN alpha-2a treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBe antigen status, amount of HBV DNA, and ALT level at 24 and 48 weeks after stopping PEG-IFN administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. HBe antigen status, amount of HBV DNA, and ALT level at 24 weeks after stopping PEG-IFN administration. 2. Changes in amount of viral antigens including HBs antigen during and after PEG-IFN administration. | — |
Countries
Japan
Contacts
Public ContactEIJI TANAKA
Shinshu University School of Medicine Department of Medicine
Outcome results
None listed